MA52235A - Anticorps anti-phf-tau et leurs utilisations - Google Patents

Anticorps anti-phf-tau et leurs utilisations

Info

Publication number
MA52235A
MA52235A MA052235A MA52235A MA52235A MA 52235 A MA52235 A MA 52235A MA 052235 A MA052235 A MA 052235A MA 52235 A MA52235 A MA 52235A MA 52235 A MA52235 A MA 52235A
Authority
MA
Morocco
Prior art keywords
phf
tau antibodies
tau
antibodies
Prior art date
Application number
MA052235A
Other languages
English (en)
Inventor
Linda Barone
Marianne Borgers
Eilyn R Lacy
Jinquan Luo
Marc Mercken
Rupesh Nanjunda
Kolen Kristof Van
John Wheeler
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA52235A publication Critical patent/MA52235A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
MA052235A 2018-03-05 2019-03-04 Anticorps anti-phf-tau et leurs utilisations MA52235A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862638535P 2018-03-05 2018-03-05

Publications (1)

Publication Number Publication Date
MA52235A true MA52235A (fr) 2021-02-17

Family

ID=67767358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052235A MA52235A (fr) 2018-03-05 2019-03-04 Anticorps anti-phf-tau et leurs utilisations

Country Status (17)

Country Link
US (2) US12234280B2 (fr)
EP (1) EP3774888A4 (fr)
JP (2) JP7362636B2 (fr)
KR (1) KR20200130350A (fr)
CN (1) CN112105639B (fr)
AU (1) AU2019232631A1 (fr)
BR (1) BR112020018112A2 (fr)
CA (1) CA3093200A1 (fr)
EA (1) EA202092088A1 (fr)
IL (1) IL277075A (fr)
JO (1) JOP20200215A1 (fr)
MA (1) MA52235A (fr)
MX (1) MX2020009277A (fr)
PH (1) PH12020551373A1 (fr)
SG (1) SG11202008579UA (fr)
TW (1) TW201946654A (fr)
WO (1) WO2019171259A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019232631A1 (en) * 2018-03-05 2020-09-24 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
CA3214310A1 (fr) 2021-03-26 2022-09-29 Rupesh Nanjunda Anticorps anti-tau et leurs utilisations
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
AU2023232448A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
AU2023232447A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025037271A1 (fr) * 2023-08-17 2025-02-20 Janssen Pharmaceutica Nv Dosage de plasma pour détecter des peptides tau dérivés du snc
WO2025122634A1 (fr) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à la protéine tau

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0940468A1 (fr) 1991-06-14 1999-09-08 Genentech, Inc. Domaine variable d'un anticorps humanisé
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
WO1993008302A1 (fr) 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Anticorps monoclonaux diriges contre la proteine tau associee aux microtubules
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
AU698383B2 (en) 1993-12-21 1998-10-29 Innogenetics N.V. Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications
ATE234324T1 (de) 1994-07-29 2003-03-15 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
CA2397991C (fr) * 2000-01-24 2017-10-24 Innogenetics N.V. Diagnostic des tauopathies
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
ATE535258T1 (de) 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
WO2004016655A1 (fr) 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation Anticorps specifique a une proteine-$g(t) centrale
ES2567198T3 (es) 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005017121A2 (fr) 2003-08-14 2005-02-24 Exelixis, Inc. Mbcats modificateurs de la voie beta-catenine et methodes d'utilisation
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
DK1711530T3 (da) 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
WO2005079479A2 (fr) 2004-02-17 2005-09-01 Absalus, Inc. Anticorps super-humanises contre les virus respiratoires syncytiaux
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
JP5160887B2 (ja) 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
EP1749839A1 (fr) 2005-07-22 2007-02-07 Novoplant GmbH Polypeptides de liaison d'antigènes F4 (K88) fimbriae
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
EP1973951A2 (fr) * 2005-12-02 2008-10-01 Genentech, Inc. Polypeptides de liaison avec des sequences de diversite limitees
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
ES2437224T3 (es) 2006-05-17 2014-01-09 Janssen Biotech, Inc. Cadenas peptídicas de variante oct-2 humana, ácidos nucleicos y métodos
EP2057193B1 (fr) 2006-08-04 2013-12-18 Novartis AG Anticorps spécifique de ephb3 et ses utilisations
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
WO2010045340A1 (fr) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Procédés d’humanisation et de maturation d’affinité d’anticorps
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2010144711A2 (fr) 2009-06-10 2010-12-16 New York University Ciblage immunologique de protéines tau pathologiques
CA2772379C (fr) 2009-08-28 2019-09-24 Rakez Kayed Anticorps liant les oligomeres de la proteine tau
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
EP2625198B1 (fr) 2010-10-07 2015-07-22 AC Immune S.A. Anticorps dirigés contre tau phosphorylée
US8940272B2 (en) * 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
CN102457701B (zh) 2010-11-02 2014-03-12 华为终端有限公司 图像显示处理方法及装置
BR112013013674A2 (pt) 2010-12-03 2016-09-06 Diamedica Inc anticorpo monoclonal de receptor anti-bradicinina b2 (bkb2r)
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CN108034005B (zh) * 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
DK2794654T3 (da) 2011-12-20 2019-08-05 Janssen Biotech Inc Anti-phf-tau-antistoffer og deres anvendelser
ITMI20120814A1 (it) 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
WO2014011972A1 (fr) 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Immunodosage de tau
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
BR112016029579A2 (pt) * 2014-06-26 2017-08-22 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
WO2016112078A2 (fr) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anticorps tau/anti-phf et leurs utilisations
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
WO2017053739A1 (fr) 2015-09-25 2017-03-30 Steen Judith Procédés et compositions pour le diagnostic et le traitement de tauopathie
US20180186855A1 (en) 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
WO2017181098A2 (fr) * 2016-04-15 2017-10-19 Visterra, Inc. Molécules d'anticorps se liant au virus zika et leurs utilisations
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
NZ748983A (en) * 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
JP6572842B2 (ja) 2016-07-15 2019-09-11 株式会社村田製作所 マルチプレクサ、高周波フロントエンド回路および通信装置
WO2018022786A1 (fr) 2016-07-26 2018-02-01 Washington University Anticorps contre le virus zika et leurs procédés d'utilisation
CA3045294A1 (fr) 2016-12-07 2018-06-14 Genentech, Inc. Anticorps anti-tau et methodes d'utilisation
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
CA3063324A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de proteines a haute concentration ayant une viscosite reduite
MX2020009278A (es) 2018-03-05 2021-01-08 Janssen Pharmaceutica Nv Ensayos para detectar la neurodegeneración.
AU2019232631A1 (en) * 2018-03-05 2020-09-24 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
WO2020223279A1 (fr) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. Anticorps vectorisés (vab) et leurs utilisations
BR112022020410A2 (pt) 2020-04-08 2023-01-03 Janssen Biotech Inc Anticorpos anti-phf-tau e usos dos mesmos
AU2021309020A1 (en) 2020-07-14 2023-03-09 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
KR20230097110A (ko) 2020-10-26 2023-06-30 얀센 파마슈티카 엔.브이. 항-타우 항체의 안전한 투여 방법
CA3199806A1 (fr) 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Procedes de reduction de la proteine tau chez des sujets humains

Also Published As

Publication number Publication date
IL277075A (en) 2020-10-29
JP2021515556A (ja) 2021-06-24
PH12020551373A1 (en) 2021-08-16
US10633435B2 (en) 2020-04-28
EP3774888A4 (fr) 2021-12-29
EA202092088A1 (ru) 2020-11-13
TW201946654A (zh) 2019-12-16
CN112105639A (zh) 2020-12-18
JOP20200215A1 (ar) 2020-09-03
BR112020018112A2 (pt) 2020-12-22
MX2020009277A (es) 2021-01-08
US12234280B2 (en) 2025-02-25
JP7362636B2 (ja) 2023-10-17
CA3093200A1 (fr) 2019-09-12
SG11202008579UA (en) 2020-10-29
AU2019232631A1 (en) 2020-09-24
JP2024009870A (ja) 2024-01-23
US20210002358A1 (en) 2021-01-07
CN112105639B (zh) 2024-09-27
US20190270793A1 (en) 2019-09-05
WO2019171259A1 (fr) 2019-09-12
EP3774888A1 (fr) 2021-02-17
KR20200130350A (ko) 2020-11-18

Similar Documents

Publication Publication Date Title
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3918323A4 (fr) Anticorps anti-gal3 et leurs utilisations
EP3625263A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3849608A4 (fr) Nouveaux anticorps anti-lilrb4 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3645563A4 (fr) Anticorps anti-fam19a5 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3894440A4 (fr) Anticorps anti-il-27 et leurs utilisations
EP3672987A4 (fr) Anticorps anti-apéline et leurs utilisations
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations
MA52094A (fr) Anticorps anti-il-27 et leurs utilisations